Stocks · News reference
Filed: 2026-07-24 AccNo: 0001193125-26-315163 Size: 249 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-14 AccNo: 0001193125-26-352186 Size: 207 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgarNewAmsterdam Pharma announced it will present multiple data presentations on obicetrapib, its novel oral CETP inhibitor for cholesterol management, at the NLA 2026 Scientific Sessions in Chicago on June 11-14, 2026. The presentations will cover clinical trial safety assessments, efficacy data from Phase 3 trials (BROADWAY and BROOKLYN), and real-world evidence on statin intolerance. The company has also granted European commercialization rights to the Menarini Group.
Read original at globenewswire-inc